We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Best Stocks to Buy in June for Long-Term Upside: Veeva Systems
Key Takeaways
VEEV stock offers investors ~80% upside potential if it returns to its highs.
Veeva is on the verge of breaking above a key technical range, and its valuation looks enticing.
The beaten-down biopharma software stock's growth outlook is strong, and it has a great balance sheet.
Investors looking to buy beaten-down tech stocks in June with long-term upside might want to consider Veeva Systems (VEEV - Free Report) .
The life sciences-focused cloud software stock is down around 45% from its peak, implying approximately 80% upside if it ever returns to its 2021 highs. VEEV reports its Q1 fiscal year 2027 financial results after the stock market closes on Wednesday, June 3.
There are legitimate concerns surrounding Veeva, including growing competition, slowing growth, and mounting fears that AI will gradually make its pharmaceutical and life sciences business software offerings obsolete.
That said, Veeva stock jumped 8% on Monday to cross above a potentially key long-term technical level after finding support near the bottom of the trading range it’s been in for the last six years.
Image Source: Zacks Investment Research
Veeva’s average Zack price target marks around 45% upside from its current levels, and it is projected to post double-digit earnings and revenue growth this year and next.
The downturn, mixed with its strong earnings growth outlook, has it trading in line with the Tech sector and over 80% below its highs in terms of forward earnings.
Buy this Tech Stock Now for 80% Upside Potential
Veeva is a cloud software company focused entirely on the pharmaceutical and life sciences industries. VEEV helps clients improve and streamline critical business functions, with software and services for research and development, regulatory processes and compliance, safety, clinical trials, marketing, and beyond.
Image Source: Zacks Investment Research
The company steadily expanded its reach over the last decade-plus, helping its clients thrive in the new digital everything world. Veeva in late 2022, announced that it would transition away from its long-term partnership agreement with Salesforce ((CRM - Free Report) ) when it expired in 2025.
More importantly, Veeva laid out plans to migrate customers from its legacy Veeva CRM (built on Salesforce) to its next-generation Vault CRM platform. Veeva is also actively expanding industry-specific AI offerings, including its AI agents.
That said, Wall Street has punished the stock because its days of 25% to 35% growth ended in FY22. Wall Street has legitimate fears that the rapid expansion and evolution of artificial intelligence could eat away at the entire enterprise software market.
Image Source: Zacks Investment Research
Veeva faces head-to-head competition with Salesforce after its split. Investors also got spooked when VEEV said in November 2025 that it expects 14 of the top 20 global pharmaceutical companies to adopt its next-generation Vault CRM product, which disappointed Wall Street since it was fewer than those using the legacy Veeva CRM platform.
Buy this Stock for Growth, Value, and AI Upside?
Still, the company grew its revenue by 16% for the second straight year in FY26 (period ended January 31). VEEV is projected to grow its FY27 revenue by ~13% and then post ~12% growth in FY28 to climb from $3.20 billion last year to $4.01 billion next year.
Image Source: Zacks Investment Research
The biopharma software company is projected to grow its adjusted earnings by over 9% this year and 11% next year, following 23% expansion in FY26. VEEV has beaten our bottom-line estimate for five years running. The chart above showcases its strong long-term earnings growth outlook
The company is also a cash cow, generating a ton of free cash flow, including 30% YoY growth in FY26.
Plus, Veeva’s balance sheet is stellar, with $6.6 billion in cash and equivalents and $9 billion in total assets against zero debt, and $1.8 billion in total liabilities. This backdrop gives the medical software company the ability to constantly pursue more organic growth opportunities across AI and beyond, and make strategic acquisitions.
VEEV stock has climbed 440% in the past decade, lagging Tech’s 540%, but topping the S&P 500’s 290% and crushing Salesforce’s 150%. This market and CRM-beating performance includes its ~45% drop from its 2021 peaks.
Image Source: Zacks Investment Research
It is trading around where it was in April 2020, while offering ~80% upside if it were to ever return to its peaks. Veeva stock climbed above its 21-week moving average after Monday’s 8% surge.
Veeva is on the verge of a potential technical breakout. Plus, its downturn mixed with is strong earnings growth outlook has it trading in line with the Tech sector and over 80% below its highs at 26X forward 12-month earnings.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Best Stocks to Buy in June for Long-Term Upside: Veeva Systems
Key Takeaways
Investors looking to buy beaten-down tech stocks in June with long-term upside might want to consider Veeva Systems (VEEV - Free Report) .
The life sciences-focused cloud software stock is down around 45% from its peak, implying approximately 80% upside if it ever returns to its 2021 highs. VEEV reports its Q1 fiscal year 2027 financial results after the stock market closes on Wednesday, June 3.
There are legitimate concerns surrounding Veeva, including growing competition, slowing growth, and mounting fears that AI will gradually make its pharmaceutical and life sciences business software offerings obsolete.
That said, Veeva stock jumped 8% on Monday to cross above a potentially key long-term technical level after finding support near the bottom of the trading range it’s been in for the last six years.
Image Source: Zacks Investment Research
Veeva’s average Zack price target marks around 45% upside from its current levels, and it is projected to post double-digit earnings and revenue growth this year and next.
The downturn, mixed with its strong earnings growth outlook, has it trading in line with the Tech sector and over 80% below its highs in terms of forward earnings.
Buy this Tech Stock Now for 80% Upside Potential
Veeva is a cloud software company focused entirely on the pharmaceutical and life sciences industries. VEEV helps clients improve and streamline critical business functions, with software and services for research and development, regulatory processes and compliance, safety, clinical trials, marketing, and beyond.
Image Source: Zacks Investment Research
The company steadily expanded its reach over the last decade-plus, helping its clients thrive in the new digital everything world. Veeva in late 2022, announced that it would transition away from its long-term partnership agreement with Salesforce ((CRM - Free Report) ) when it expired in 2025.
More importantly, Veeva laid out plans to migrate customers from its legacy Veeva CRM (built on Salesforce) to its next-generation Vault CRM platform. Veeva is also actively expanding industry-specific AI offerings, including its AI agents.
That said, Wall Street has punished the stock because its days of 25% to 35% growth ended in FY22. Wall Street has legitimate fears that the rapid expansion and evolution of artificial intelligence could eat away at the entire enterprise software market.
Image Source: Zacks Investment Research
Veeva faces head-to-head competition with Salesforce after its split. Investors also got spooked when VEEV said in November 2025 that it expects 14 of the top 20 global pharmaceutical companies to adopt its next-generation Vault CRM product, which disappointed Wall Street since it was fewer than those using the legacy Veeva CRM platform.
Buy this Stock for Growth, Value, and AI Upside?
Still, the company grew its revenue by 16% for the second straight year in FY26 (period ended January 31). VEEV is projected to grow its FY27 revenue by ~13% and then post ~12% growth in FY28 to climb from $3.20 billion last year to $4.01 billion next year.
Image Source: Zacks Investment Research
The biopharma software company is projected to grow its adjusted earnings by over 9% this year and 11% next year, following 23% expansion in FY26. VEEV has beaten our bottom-line estimate for five years running. The chart above showcases its strong long-term earnings growth outlook
The company is also a cash cow, generating a ton of free cash flow, including 30% YoY growth in FY26.
Plus, Veeva’s balance sheet is stellar, with $6.6 billion in cash and equivalents and $9 billion in total assets against zero debt, and $1.8 billion in total liabilities. This backdrop gives the medical software company the ability to constantly pursue more organic growth opportunities across AI and beyond, and make strategic acquisitions.
VEEV stock has climbed 440% in the past decade, lagging Tech’s 540%, but topping the S&P 500’s 290% and crushing Salesforce’s 150%. This market and CRM-beating performance includes its ~45% drop from its 2021 peaks.
Image Source: Zacks Investment Research
It is trading around where it was in April 2020, while offering ~80% upside if it were to ever return to its peaks. Veeva stock climbed above its 21-week moving average after Monday’s 8% surge.
Veeva is on the verge of a potential technical breakout. Plus, its downturn mixed with is strong earnings growth outlook has it trading in line with the Tech sector and over 80% below its highs at 26X forward 12-month earnings.